Emmaus Life Sciences, Inc. EMMA

OTC: EMMA | ISIN: US29137T1016   22/05/2025
0,013 USD (-7,14%)
(-7,14%)   22/05/2025

15 mei 2025 · Emmaus Life Sciences Reports Quarterly Financial Results · Persbericht

15 april 2025 · Emmaus Life Sciences Reports 2024 Financial Results · Persbericht

10 september 2024 · Emmaus Life Sciences Reports Quarterly Financial Results · Persbericht

23 juli 2024 · Emmaus Life Sciences Announces Willis C. Lee as Chief Executive Officer · Persbericht

12 juli 2024 · Emmaus Life Sciences Announces Outcome of FDA Inspection of Postmarketing Adverse Drug Experience Compliance Program · Persbericht

3 juli 2024 · Emmaus Life Sciences Reports 2023 Financial Results · Persbericht

15 april 2024 · Emmaus Life Sciences Reports Delayed Filing of Annual Report · Persbericht

2 februari 2024 · Emmaus Life Sciences Receives Marketing Authorization for Puerto Rico · Persbericht

23 augustus 2023 · Emmaus Life Sciences Reports Management Changes · Persbericht

14 augustus 2023 · Emmaus Life Sciences Reports Q2 2023 Financial Results · Persbericht

13 juli 2023 · Emmaus Life Sciences Receives Marketing Authorization for Endari® in Oman · Persbericht

31 mei 2023 · Emmaus Life Sciences Receives Endari® Marketing Authorization from the Bahrain NHRA · Persbericht

15 mei 2023 · Emmaus Life Sciences Reports Q1 2023 Financial Results and Provides Business Update · Persbericht

3 april 2023 · Emmaus Life Sciences Provides Interim Shipment Data · Persbericht

31 maart 2023 · Emmaus Life Sciences Reports 2022 Financial Results and Provides Business Update · Persbericht

20 december 2022 · Dr. Niihara Meets with Local Indian Governor · Persbericht

19 december 2022 · Dr. Niihara Feted by Indian Government in Recognition of the Development of Endari® · Persbericht

7 december 2022 · Endari® Receives Kuwaiti Marketing Authorization · Persbericht

17 november 2022 · Emmaus Life Sciences Receives Endari® Marketing Authorization from the Qatar Ministry of Public Health · Persbericht

15 november 2022 · /C O R R E C T I O N -- Emmaus Life Sciences, Inc./ · Persbericht

Mijn selecties